Edition:
India

Seres Therapeutics Inc (MCRB.OQ)

MCRB.OQ on NASDAQ Stock Exchange Global Select Market

2.45USD
1:30am IST
Change (% chg)

$0.17 (+7.46%)
Prev Close
$2.28
Open
$2.28
Day's High
$2.46
Day's Low
$2.24
Volume
206,667
Avg. Vol
96,675
52-wk High
$9.75
52-wk Low
$2.02

Latest Key Developments (Source: Significant Developments)

MTIG - Working With FDA For Evaluation Of Safety Parameters Related To Microbiota-Based Therapeutic Products
Monday, 17 Jun 2019 

June 17 (Reuters) - MTIG::MTIG - STATEMENT ON FDA SAFETY ALERT REGARDING USE OF FECAL MICROBIOTA FOR TRANSPLANTATION AND RISK OF SERIOUS ADVERSE REACTIONS.MTIG - WORKING WITH FDA TO DEVELOP GUIDELINES FOR APPLICATION OF PHARMACEUTICAL DEVELOPMENT CRITERIA RELATED TO MICROBIOTA-BASED THERAPEUTICS.MTIG - WORKING WITH FDA FOR EVALUATION OF SAFETY PARAMETERS RELATED TO MICROBIOTA-BASED THERAPEUTIC PRODUCTS.  Full Article

Seres Therapeutics Inc Announces Proposed Public Offering Of Common Stock
Thursday, 13 Jun 2019 

June 12 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SERES THERAPEUTICS INC - COMMENCING AN UNDERWRITTEN REGISTERED PUBLIC OFFERING OF $60.0 MILLION OF SHARES OF ITS COMMON STOCK..  Full Article

Seres Therapeutics Says Board Appointed Marcus Chapman As Principal Financial And Accounting Officer
Friday, 19 Apr 2019 

April 18 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS SAYS BOARD APPOINTED MARCUS CHAPMAN AS PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER OF COMPANY - SEC FILING.  Full Article

Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration With Astrazeneca
Monday, 11 Mar 2019 

March 11 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS ANNOUNCES MICROBIOME IMMUNO-ONCOLOGY FOCUSED COLLABORATION WITH ASTRAZENECA.SERES THERAPEUTICS INC - SERES TO RECEIVE $20 MILLION AND FINANCIAL SUPPORT FOR RESEARCH ACTIVITIES.SERES THERAPEUTICS - COLLABORATION FOCUSED ON FURTHER ELUCIDATING POTENTIAL OF MICROBIOME THERAPEUTICS TO AUGMENT IMMUNO-ONCOLOGY TREATMENT FOR CANCER.SERES THERAPEUTICS INC - ASTRAZENECA WILL ALSO REIMBURSE SERES FOR RESEARCH ACTIVITY RELATED TO COLLABORATION.SERES THERAPEUTICS INC - SERES WILL MAINTAIN RIGHTS TO ONCOLOGY TARGETED MICROBIOME THERAPEUTIC CANDIDATES.SERES THERAPEUTICS INC - ASTRAZENECA WILL OBTAIN OPTION TO NEGOTIATE FOR RIGHTS TO THOSE PROGRAMS AND OTHER INVENTIONS ARISING OUT OF COLLABORATION.  Full Article

Seres Therapeutics Reports Net Loss Of $21.3 Mln For Q4 Of 2018
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES.SERES THERAPEUTICS INC - REPORTED A NET LOSS OF $21.3 MILLION FOR Q4 OF 2018, AS COMPARED TO A NET LOSS OF $29.0 MILLION FOR SAME PERIOD IN 2017.SERES THERAPEUTICS - BASED ON CURRENT OPERATING PLAN, CASH RESOURCES ARE EXPECTED TO FUND OPERATING EXPENSES, CAPEX REQUIREMENTS, EXCLUDING ITEMS, INTO Q4 OF THIS YEAR.  Full Article

Seres Therapeutics Reports Qtrly Loss Per Share $0.68
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES.SERES ENDED Q2 WITH APPROXIMATELY $96.1 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.QTRLY TOTAL REVENUE $4.6 MILLION VERSUS $3 MILLION.QTRLY LOSS PER SHARE $0.68.Q2 EARNINGS PER SHARE VIEW $-0.63, REVENUE VIEW $6.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SER-287 IN TREATMENT OF PEDIATRIC ULCERATIVE COLITIS.SERES THERAPEUTICS INC - SER-287 PHASE 1B MICROBIOME DATA ARE EXPECTED IN EARLY 2018.  Full Article

Seres Therapeutics Q3 net loss per share ‍$0.17​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Seres Therapeutics Inc : :Seres Therapeutics reports third quarter 2017 financial results and provides update on operational progress.Seres Therapeutics - ‍positive results from SER-287 phase 1B study in mild-to-moderate ulcerative colitis; co to move program into further development​.Seres therapeutics Inc - ‍in early 2018, co anticipates results from SER-262 phase 1B study in primary C. Difficile infection​.Seres Therapeutics Inc qtrly net loss per share ‍$0.17​.Seres Therapeutics Inc qtrly ‍total revenue $23 million versus $13 million​.  Full Article